Effect of Mirtazapine Treatment on Serum Levels of Brain-Derived Neurotrophic Factor and Tumor Necrosis Factor-α in Patients of Major Depressive Disorder with Severe Depression
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study evaluated the clinical efficacy of mirtazapine and its effect on serum brain-derived neurotrophic factor (BDNF) and tumor necrosis factor-α (TNF-α) levels in patients of major-depressive disorder (MDD) with severe depression. METHODS: Patients (aged 18-60) with MDD diagnosed by DSM-IV criteria, and Hamilton Rating Scale for Depression (HAM-D) score ≥25 were included (n = 30). Mirtazapine was given in the doses of 30 mg/day. All patients were followed up for 12 weeks for the evaluation of clinical efficacy, safety along with serum BDNF and TNF-α levels. RESULTS: HAM-D score at the start of treatment was 30.1 ± 1.92, which significantly (p < 0.05) reduced to 13.47 ± 1.77 at 12 weeks of treatment. In responders, mean serum BDNF levels at the start of treatment were 2.32 ± 0.3 ng/ml, which significantly (p < 0.05) increased to 2.79 ± 0.33 ng/ml at 12 weeks of treatment and mean serum TNF-α levels at the start were 5.18 ± 0.67 pg/ml, which significantly decreased to 4.36 ± 0.72 pg/ml (p < 0.05) at 12 weeks of treatment. CONCLUSION: Our results suggest that mirtazapine is effective and well tolerated in severely depressed patients and treatment response is associated with an increase in serum BDNF and a decrease in serum TNF-α levels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, however, Gupta et al. (203) found that successful treatment with mirtazapine led to a decrease in serum TNF-α levels.”
From Cytokine Research in Depression: Principles, Challenges, and Open Questions (2019) · cites this paper as [203]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
A molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129
Sen, S., Duman, R., & Sanacora, G. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.005 · Cited by 1,232
Brunoni, A. R., Lopes, M., & Fregni, F. (2008) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009309 · Cited by 972
Hannestad, J., DellaGioia, N., & Bloch, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.132 · Cited by 914
A Review of the Pharmacological and Clinical Profile of Mirtazapine
Anttila, S. A. K., & Leinonen, E. V. J. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00198.x · Cited by 795
Critical Role of Brain-Derived Neurotrophic Factor in Mood Disorders
Hashimoto, K., Shimizu, E., & Iyo, M. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.02.003 · Cited by 522
Tuglu, C., Kara, S. H., Caliyurt, O., Vardar, E., & Abay, E. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1566-z · Cited by 391
Effect of treatment on serum brain–derived neurotrophic factor levels in depressed patients
Gonul, A. S., Akdeniz, F., Taneli, F., Donat, O., Eker, Ç., & Vahip, S. (2005) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-005-0578-6 · Cited by 375
Cited by
Liu, J. J., Wei, Y. B., Strawbridge, R., Bao, Y., Chang, S., Shi, L., Que, J., Gadad, B. S., Trivedi, M. H., Kelsoe, J. R., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0474-5 · Cited by 429
Cytokine Research in Depression: Principles, Challenges, and Open Questions
Himmerich, H., Patsalos, O., Lichtblau, N., Ibrahim, M. A. A., & Dalton, B. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00030 · Cited by 313
Haroon, E., Daguanno, A. W., Woolwine, B. J., Goldsmith, D. R., Baer, W. M., Wommack, E. C., Felger, J. C., & Miller, A. H. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.05.026 · Cited by 291
“TNF has been one of the most measured markers of inflammation in this literature, with multiple studies showing elevations in TNF in non-responders following treatment compared to treatment responders (Eller et al., 2008; Gupta et al., 2016; Lanquillon et al., 2000; Strawbridge et al., 2015).”
ResultEffect of antidepressant treatment on peripheral inflammation markers – A meta-analysis
Więdłocha, M., Marcinowicz, P., Krupa, R., Janoska-Jaździk, M., Janus, M., Dębowska, W., Mosiołek, A., Waszkiewicz, N., & Szulc, A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.04.026 · Cited by 233
“Animal studies followed by clinical trials confirmed that antidepressant drugs act not only on the neurotransmission but also result in increases of BNDF levels (Gupta et al., 2016).”
BackgroundArteaga-Henríquez, G., Simon, M. S., Burger, B., Weidinger, E., Wijkhuijs, A., Arolt, V., Birkenhager, T. K., Musil, R., Müller, N., & Drexhage, H. A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00458 · Cited by 215
“, 2016 (51) Mirtazapine (NaSSA) TNFα Higher response rates compared”
BackgroundIntestinal Microbiota Influences Non-intestinal Related Autoimmune Diseases
Opazo, M. C., Ortega-Rocha, E. M., Coronado-Arrázola, I., Bonifaz, L. C., Boudin, H., Neunlist, M., Bueno, S. M., Kalergis, A. M., & Riedel, C. A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00432 · Cited by 179
“Interestingly, a decreased serum BDNF levels were observed in patients with major depressive disorders (Pedrotti Moreira et al., 2017) and pharmacological treatment that increases BDNF levels proved to be beneficial for depressive patients (Gupta et al., 2016).”
BackgroundCorreia, A. S., Cardoso, A., & Vale, N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082081 · Cited by 155
Growth factors as clinical biomarkers of prognosis and diagnosis in psychiatric disorders
Galvez-Contreras, A. Y., Campos-Ordonez, T., Lopez-Virgen, V., Gomez-Plascencia, J., Ramos-Zuniga, R., & Gonzalez-Perez, O. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.08.004 · Cited by 112
Mosiołek, A., Mosiołek, J., Jakima, S., Pięta, A., & Szulc, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153377 · Cited by 87
“[40] 2017 B Clinical Trial n = 60 (agomelatine = 30 fluoxetine = 30) 12 serum BDNF Fluoxetine, Agomelatine YES Agomelatine responders—serum BDNF level significantly increased at 12 weeks after treatment.”
BackgroundMethodAgomelatine-induced modulation of brain-derived neurotrophic factor (BDNF) in the rat hippocampus
Lu, Y., Ho, C. S., McIntyre, R. S., Wang, W., & Ho, R. C. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.09.003 · Cited by 76
Higher Baseline Interleukin-1β and TNF-α Hamper Antidepressant Response in Major Depressive Disorder
Benedetti, F., Poletti, S., Vai, B., Mazza, M. G., Lorenzi, C., Brioschi, S., Aggio, V., Branchi, I., Colombo, C., Furlan, R., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.11.009 · Cited by 62
Pharmacological update of mirtazapine: a narrative literature review
Hassanein, E. H. M., Althagafy, H. S., Baraka, M. A., Abd‐alhameed, E. K., & Ibrahim, I. M. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02818-6 · Cited by 61
“Previous research has suggested that MTZ treatment for major depressive disorders has anti-inflammatory effects and decreases tumor necrosis factor (TNF)-α levels (Gupta et al. 2016).”
BackgroundBDNF plasma levels and genotype in depression and the response to electroconvulsive therapy
Ryan, K. M., Dunne, R. A., & McLoughlin, D. M. (2018) · Brain stimulation · doi:10.1016/j.brs.2018.05.011 · Cited by 64
Gasparini, A., Callegari, C., Lucca, G., Bellini, A., Caselli, I., & Ielmini, M. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4425 · Cited by 61
Chen, S., Jiang, H., Liu, Y., Hou, Z., Yue, Y., Zhang, Y., Zhao, F., Xu, Z., Li, Y., Mou, X., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06832-6 · Cited by 50
Li, M., Shao, H., Zhang, X., & Qin, B. (2016) · Inflammation · doi:10.1007/s10753-016-0402-7 · Cited by 50
“In contrast, antidepressant medication can decrease the concentration of pro-inflammatory cytokines [3, 4].”
Gupta, K., Gupta, R., Bhatia, M. S., Tripathi, A. K., & Gupta, L. K. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.963 · Cited by 54
Self-citationWang, W., Yang, J., Xu, J., Yu, H., Liu, Y., Wang, R., Ho, R., Ho, C. S. H., & Pan, F. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.11.015 · Cited by 49
Protective effects of mirtazapine and chrysin on experimentally induced testicular damage in rats
El‐Sisi, A. E., El‐Sayad, M. E., & Abdelsalam, N. M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.09.022 · Cited by 40
Analysis of cytokine levels, T regulatory cells and serotonin content in patients with depression
Obermanns, J., Krawczyk, E., Juckel, G., & Emons, B. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15205 · Cited by 40
Major depressive disorders accompanying autoimmune diseases – Response to treatment
Białek, K. I., Czarny, P. L., Strycharz, J., & Śliwiński, T. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109678 · Cited by 34
Personalized Medicine Using Neuroimmunological Biomarkers in Depressive Disorders
Chi, S., & Lee, M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020114 · Cited by 33
“Treatment with certain antidepressants indeed resulted in such decline, but it is not clear if the effects are pharmacologic or due to a change in clinical symptom severity [19].”
BackgroundZhong, X., Cao, W., Zhao, H., Chen, L., Cao, J., Wei, L., Tang, Y., Zhong, J., Xiao, X., Zu, X., et al. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.11.001 · Cited by 28
“In contrast, anti-depressant medication can decrease the concentration of pro-inflammatory cytokines (Hashimoto et al. 2015; Gupta et al. 2016).”
BackgroundPark, Y., & Lee, B.-H. (2018) · Psychiatry Investigation · doi:10.30773/pi.2018.03.31 · Cited by 28
Perković, M. N., Gredičak, M., Šagud, M., Erjavec, G. N., Uzun, S., & Pivac, N. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2200937 · Cited by 28
Night shift hormone: How does melatonin affect depression?
Kholghi, G., Eskandari, M., Saadlou, M.-S. S. Q., Zarrindast, M., & Vaseghi, S. (2022) · Physiology & Behavior · doi:10.1016/j.physbeh.2022.113835 · Cited by 28
Simon, M. S., Burger, B., Weidinger, E., Arteaga-Henríquez, G., Zill, P., Musil, R., Drexhage, H. A., & Müller, N. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.615261 · Cited by 26
“However, conflicting results exist (63, 64).”
Fernandes, B. M., Scotti-Muzzi, E., & Soeiro‐de‐Souza, M. G. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03240-8 · Cited by 26
Groeger, D., Murphy, E. F., Tan, H. T., Larsen, I., O’Neill, I. J., & Quigley, E. M. M. (2022) · Neurogastroenterology & Motility · doi:10.1111/nmo.14477 · Cited by 26
Hafez, H. M., Ibrahim, M. A., Abdelzaher, W. Y., Gad, A. A., Hafez, S. M. N. A., & Abdel-Gaber, S. A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108174 · Cited by 24
miR-124 antagonizes the antidepressant-like effects of standardized gypenosides in mice
Yi, L., Mu, R.-H., Dong, S., Wang, S., Li, C., Geng, D., & Liu, Q. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118758304 · Cited by 23
“BDNF is commonly decreased in depressed patients and depressive-like animals (Bus et al., 2015; Chourbaji et al., 2011; Gupta et al., 2016; Urani et al., 2005), and its role in antidepressant treatments is much clearer (Castren and Kojima, 2017).”
BackgroundTafseer, S., Gupta, R., Ahmad, R. S., Jain, S., Bhatia, M. S., & Gupta, L. K. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.173073 · Cited by 20
Self-citationBenedetti, F., Dallaspezia, S., Melloni, E. M. T., Lorenzi, C., Zanardi, R., Barbini, B., & Colombo, C. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.740686 · Cited by 20
Cutuli, D., & Sampedro-Piquero, P. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220624111855 · Cited by 16
Yoshimura, R., Okamoto, N., Chibaatar, E., Natsuyama, T., & Ikenouchi, A. (2023) · Biomedicines · doi:10.3390/biomedicines11020584 · Cited by 15
“These results are consistent with those of Zhou et al. [39] and did not contradict our previous report demonstrating that early changes in serum BDNF levels (from week 0 and week 4) did not predict the response to treatment with SSRIs [57].”
BackgroundResultInfluentialAssociation between programmed death-1 pathway and major depression
Huang, K.-W., & Huang, T. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2023.2209876 · Cited by 13
“…neurotrophins (Huang et al. 2008; Birkenhager et al. 2012; Lee et al. 2014; Nomoto et al. 2015; Zhang et al. 2015), stress, inflammation (Gupta et al. 2016, 2017), and neurogenesis, excitatory and inhibitory neurotransmission, mitochondrial dysfunction and oxidative stress, as well as…”
BackgroundEl‐Sisi, A. E., Sokar, S. S., Shalaby, M. F., & Abu-Risha, S. E.-S. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933435 · Cited by 12
Kim, J., Kang, H., Kim, J., Choi, W., Lee, J., Kim, S., & Shin, I. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115198 · Cited by 10
Casulari, L. A., de Castro, L. F., Kessler, I. M., Mendonça, J. L., & Gonzaga, M. D. F. D. M. (2019) · Journal of Medical Case Reports · doi:10.1186/s13256-019-2071-2 · Cited by 8
Deng, J., Song, L., Yang, Z., Zheng, S., Du, Z., Luo, L., Liu, J., Jin, X., & Yang, J. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.03.015 · Cited by 9
Gold, P. W., & Wong, M. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03019-8 · Cited by 7
“Instead, data indicate that the BDNF is the molecule involved in the mechanism of action of agents such as Effexor TM [61], Remeron TM [62], Wellbutrin TM [63], ketamine [44], and others.”
Oh, H., Kong, N. Y., Jung, S.-W., Kim, H.-C., Kim, S., Kang, J., & Lee, H. (2025) · Psychiatry Investigation · doi:10.30773/pi.2025.0013 · Cited by 7
“Also, some anti-depressants are known to affect cytokine levels 67,68 ; however, since this was a retrospective study, patients were treated with different medications according to a psychiatrist’s judgment.”
Lee, I., Sheu, W. H., Lee, W., & Chen, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-23791-8 · Cited by 8
A review of epigenetics in human consciousness
Liester, M. B., & Sullivan, E. E. (2019) · Cogent Psychology · doi:10.1080/23311908.2019.1668222 · Cited by 8
Lin, M., Zhu, J., Yuan, Y., Ren, L., Qian, M., Shen, Z., Shao, Y., & Shen, X. (2018) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2017.0053 · Cited by 6
“Many researchers found that BDNF did not seem to cause depressive behaviors, but it did influence the effect of antidepressant drugs (Fornaro et al. , 2015; Bus and Molendijk, 2016; Gupta et al. , 2016; Martinotti et al. , 2016; Nase et al. , 2016).”
Choi, W., Stewart, R. J., Kang, H., Kim, J., Kim, H. K., Kang, H., Lee, J., Kim, S., & Kim, J. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.01.029 · Cited by 8
Davis, M. P. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_102-1 · Cited by 5
Use of Serum Biomarkers to Aid Antidepressant Selection in Depressive Patients
Kang, H., Kim, J., Choi, W., Lee, J., Kim, S., Shin, I., & Kim, J. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1071 · Cited by 5
“Studies on the associations of serotonin and folate levels with mirtazapine use are needed, because cytokine and BDNF levels have rarely been used as predictive markers of the response to this agent [33,34].”
Correia, A. S., Torrado, M., Costa-Coelho, T., Carvalho, E. D., Inteiro-Oliveira, S., Diógenes, M. J., Pêgo, A. P., Santos, S. D., Sebastião, A. M., & Vale, N. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123133 · Cited by 4
Arockiaraj, N., Gupta, R., Ahmad, R. S., Halder, S., & Bhatia, M. S. (2023) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2023.2287754 · Cited by 2
“…study ( n = 30) found that serum tNF-α significantly decreased after 12 weeks of treatment with mirtazapine in patients of MDD with severe depression (Gupta et al., 2016). however, in our study, antidepressant combination therapy from the treatment initiation resulted in an early reduction (8…”
ResultSelf-citationMaková, M., Kašparová, S., Bačiak, L., Gogola, D., Sumbalová, Z., Brucknerová, I., Bukatová, S., & Dubovický, M. (2025) · Neurochemistry International · doi:10.1016/j.neuint.2025.105981 · Cited by 1
Davis, M. P. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_102
Kim, J., Kang, H., Kim, J.-W., Kim, H.-Y., Jhon, M., Lee, J., Kim, S., & Shin, I. (2025) · BJPsych Open · doi:10.1192/bjo.2025.10837 · Cited by 1
“For example, higher baseline TNF-α levels predicted a more favourable antidepressant response, 24,25 adding further complexity to the interpretation of TNF-α as a predictive biomarker.”
Ramawat, R. B., Quraishi, R., Deep, R., Kumar, R., Mishra, A. K., & Jain, R. (2025) · Indian Journal of Psychological Medicine · doi:10.1177/02537176251375295
Kim, J., Kang, H., Kim, J.-W., Jhon, M., Lee, J., Kim, S., & Shin, I. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116741
Breit, S. (2026) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20260006
Mirtazapine Induces Lipocalin-Type Prostaglandin D Synthase Expression in Brain Pericytes
Narita, A., Nakano‐Doi, A., Nishiyama, R., Sawano, T., Fukushima, K., Matsuyama, T., & Nakagomi, T. (2026) · Biomolecules · doi:10.3390/biom16070945
“Accordingly, accumulating evidence shows that MTZ modulates neuroinflammation [42], including regulating NF-κ B/TLR4 signaling [43].”
Selaković, D., Mitrović, M. M., Janjic, V. S., Milovanovic, D., Jovicic, N. U., Fetahović, E., Milosavljević, J., & Rosic, G. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146142
Rahimi, K., Afandak, S. R., Razavi, F., Segoli, A., & Maharlooei, F. S. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000005289
“Moreover, several antidepressant medications – such as mirtazapine [ 39–41 ] and escitalopram [ 42 , 43 ] – have been reported to elevate BDNF levels while simultaneously reducing markers of oxidative stress.”
Biomarkers for mood disorders: A scoping review of research from India
Tholasappa, V., Baidebettu, V. P., Vijaykumar, H. G., Reddy, P. V., Arasappa, R., & Kesavan, M. (2026) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry_282_26
Investigation of C-reactive Protein (CRP) in Never-Treated Depressed Patients
Elrassas, H. H., Mohamed, A. S., Shaker, N. M., Sultan, M. A.-R., Zeidan, T. M. S., & Abdeen, M. S. (2026) · The Open Psychology Journal · doi:10.2174/0118743501453955260830101707
Núñez, J. M., Zani, G. D. S., da Silva, W., Gressler, R. P., Firpo, G., Lima, M. D. O., Fischer, G., & Hübner, S. D. O. (2026) · Arquivo Brasileiro de Medicina Veterinária e Zootecnia · doi:10.1590/1678-4162-13712
Metadata
- Authors
- Gupta, R., Gupta, K., Tripathi, A. K., Bhatia, M. S., & Gupta, L. K.
- Affiliations
- University College of Medical Sciences (IN)
- Lady Hardinge Medical College (IN)
- Venue
- Pharmacology
- Publisher
- S. Karger AG
- Published
- 2016
- Volume
- 97
- Issue
- 3-4
- Pages
- 184-188
- ISSN
- 0031-7012 (ISSN-L)
- 1423-0313
- OpenAlex
- W2265991184
- Cited by
- 61
- References
- 28
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 1 · 2023: 8 · 2022: 4 · 2021: 11 · 2020: 3 · 2019: 7 · 2018: 8 · 2017: 4 · 2016: 2
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- mirtazapine, major depressive disorder, severe depression, brain-derived neurotrophic factor, TNF-α, serum biomarkers, antidepressant efficacy, treatment response, drug safety
- MeSH terms
- Mirtazapine, Adolescent, Adult, Antidepressive Agents, Tricyclic, Depression, Major Depressive Disorder, Depressive Disorder, Major, Female, Humans, Male, Mianserin, Middle Aged, Tumor Necrosis Factor-alpha, Treatment Outcome, Brain-Derived Neurotrophic Factor, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.